In this issue:
Clinical characteristics and outcomes in patients with COVID-19 and MS
Pathological correlates of the magnetisation transfer ratio in MS
Real-world experience with aHSCT and alemtuzumab for aggressive MS
Wearable sensors to quantify gait alterations associated with disability in progressive MS
Brain volume loss and long-term disability outcomes in patients with MS treated with teriflunomide
Ten-year disease progression in MS
Health economics and patient outcomes of HSCT vs DMTs for RRMS in the US
Gd enhancement on cranial MRI in MS is age dependent
Contribution of enhancing lesions in monitoring MS treatment
Economic burden of MS by disability severity in Australia in 2017
Please login below to download this issue (PDF)